Olink Holding AB, a proteomics platform provider, has filed Amendment No 1 to Form F-1 Registration Statement on March 18, 2021 with the U.S. Securities and Exchange Commission to announce terms for its IPO.
The company plans to raise $300 million by offering 17.6 million shares at a price range of $16 to $18. Assuming a successful IPO at the midpoint of the proposed price, the company expects a market capitalization of $2 billion.
The company enables and accelerates the field of proteomics by providing a platform of products and services, developed with key opinion leaders (KOLs), that are deployed across major biopharmaceutical companies and leading clinical and academic institutions.
The Uppsala, Sweden-based company was founded in 2004 and booked $54 million in sales for the 12 months ended December 31, 2020. It plans to list on the Nasdaq Global Market under the symbol “OLK.” Sachs, Morgan Stanley and SVB Leerink are underwriters of the IPO.
The company engages Advokatfirman Delphi KB, Stockholm, Sweden and Goodwin Procter LLP as US Securities Counsel, and ÖhrlingsPricewaterhouseCoopers AB as Independent Auditor.
#ipo #nasdaq #Olink #proteomic #platform
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected]
